wherein A is H, CH 3, OCH 3, CF 3 or NO 2; R 3 is N R 26; wherein R 26 is hydrogen or C 1 C 6 alkyl; R 4 is hydrogen, C 1 6 alkyl, or CH 2 R 12; R 6 is independently an amino, a nitro, NHC O R 10, NHC O O R 10, C O NHR 10, OC O NHR 10, or halo; R 10 is hydrogen, C 1 6 alkyl, phenyl, naphthyl, C 3 6 cycloalkyl, norbornyl, or adamantyl; q is 0, 1, or 2; R 5 is a direct bond, NH or C 1 C 6 alkylene; or R 5 and X together with the atoms to which they are attached form a 6 or 7 membered ring, wherein said 6 or 7 membered ring contains a linking group C O O or OC O; R 7 is hydrogen, methyl, CH R 17 R 18, C O O R 18, or OC O R 18; wherein R 17 is hydrogen or C 1 6 alkyl; R 18 is hydrogen, C 1 6 alkyl, CH R 19 R 20, phenyl, naphthyl, C 3 6 cycloalkyl, norbornyl, adamantyl, a natural or unnatural amino acid or a peptide; R 19 is hydrogen or C 1 6 alkyl; R 20 is hydrogen, C 1 6 alkyl; R 8 is H or C 1 6 alkyl; R 9 is hydrogen, C 1 6 alkyl, phenyl, naphthyl, C 3 6 cycloalkyl, norbornyl, adamantyl, a natural or unnatural amino acid or a peptide; R 11 and R 12 are hydrogen, C 1 6 alkyl, or either or both of R 11 and R 12 contain a reactive group on to which a linker and or one or more of compound W can be added; E is C 1 C 6 alkylene; G is N or CR 16; R 16 is hydrogen or methyl; compound W is one or more amino acids, one or more sugars, polymeric ethers, C 1 6 alkylene phenyl NH C O R 15, folic acid, ?± v ?? 3 integrin RGD binding peptide, tamoxifen, endoxifen, EGFR epidermal growth factor receptor antibody conjugates, kinase inhibitors, diazoles, triazoles, oxazoles, erlotinib, and mixtures thereof; and Z is independently one or more halo or nitro, or one or more counterions sufficient to balance the charge of the compound letrozole vs tamoxifen